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Background: We have used a sensitized ENU mutagenesis screen to produce mouse lines that carry mutations in
genes required for epigenetic regulation. We call these lines Modifiers of murine metastable epialleles (Mommes).
Results: We report a basic molecular and phenotypic characterization for twenty of the Momme mouse lines, and
in each case we also identify the causative mutation. Three of the lines carry a mutation in a novel epigenetic
modifier, Rearranged L-myc fusion (Rlf), and one gene, Rap-interacting factor 1 (Rif1), has not previously been
reported to be involved in transcriptional regulation in mammals. Many of the other lines are novel alleles of
known epigenetic regulators. For two genes, Rlf and Widely-interspaced zinc finger (Wiz), we describe the first mouse
mutants. All of the Momme mutants show some degree of homozygous embryonic lethality, emphasizing the
importance of epigenetic processes. The penetrance of lethality is incomplete in a number of cases. Similarly,
abnormalities in phenotype seen in the heterozygous individuals of some lines occur with incomplete penetrance.
Conclusions: Recent advances in sequencing enhance the power of sensitized mutagenesis screens to identify the
function of previously uncharacterized factors and to discover additional functions for previously characterized
proteins. The observation of incomplete penetrance of phenotypes in these inbred mutant mice, at various stages
of development, is of interest. Overall, the Momme collection of mouse mutants provides a valuable resource for
researchers across many disciplines.Background
Mutagenesis screens for modifiers of position effect
variegation in Drosophila have played a defining role in
the development of the field of epigenetics [1]. The
screens used a fly strain that showed variegated expres-
sion of the white (w) locus, resulting in red and white
patches in the eye, as a result of the stochastic establish-
ment of epigenetic state. The genes identified by these
screens turn out to have pivotal roles in gene silencing
[2-4]. We have designed a similar screen in the mouse,* Correspondence: e.whitelaw@latrobe.edu.au
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reproduction in any medium, provided the orusing a green fluorescent protein (GFP) transgene
that shows variegated expression in red blood cells. Off-
spring of N-ethyl-N-nitrosourea (ENU)-treated males are
screened for changes in the percentage of erythrocytes
expressing GFP; this is a screen for dominant effects.
Each mutant line is named a Modifier of murine metasta-
ble epiallele Dominant, MommeD [5]. The underlying
mutations have been identified and published for nine
lines and the mutations occur in DNA methyltransferases
(Dnmt1 and Dnmt3b), chromatin remodelers (Smarca5
and Baz1b), a histone deacetylase (Hdac1), a transcrip-
tional co-repressor (Trim28), a eukaryotic translation ini-
tiation factor (eIF3h) [6-10] and a previously unknown
gene, Smchd1, now shown to be required for X-inactivation
in the mouse [11,12]. Recently, Smchd1 has beenal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in SMCHD1 have been shown to be tightly associated
with the human disease facioscapulohumeral dystrophy
type 2 (FSHD2) [14].
Results and discussion
Identification of Momme mutants
We have now screened a total of approximately 5,000
G1 offspring, recovered 42 MommeD lines and identified
the underlying mutations in 29 cases. These lines carry
mutations in 18 unique genes (Table 1). A number of
the genes have been hit more than once. Based on their
effect on GFP expression, 14 lines were classified as sup-
pressors of variegation, that is, the mutation increased
the percentage of erythrocytes expressing GFP, and 15
lines were classified as enhancers of variegation, that is,
the mutation decreased the percentage of erythrocytes
expressing GFP (Table 1). Here we report, for the first
time, the underlying mutations in 20 MommeD lines,
which carry mutations in 10 unique genes.
The experimental pipeline for the screen is shown in
Figure 1. In brief, ENU mutagenesis was carried out as
described previously [5] and mapping was carried out
following a G2 backcross to Line3C (a C57BL/6J strain
carrying the same GFP transgene array at the same loca-
tion) using traditional microsatellite and SNP genotyping
or an Illumina GoldenGate SNP genotyping assay. Map-
ping intervals for the latter group are shown as Manhattan
plots in Additional file 1.
To identify the underlying mutations, several different
strategies have been used. In ten cases, the mutation was
identified following whole exome deep sequencing of
DNA from one mutant mouse from the MommeD in-
bred colony. For these, variants were called within the
intervals linked to the causative mutation. For some
lines, variant calling was extended to exome-wide, to as-
sess for passenger mutations but only a small number
was found (<10). These did not reflect the typical ENU
sequence bias (T/A) [30] and probably represent normal
background mutations.
In two instances, we have used a custom capture array
to specifically enrich for DNA from a 4.2 Mbp interval
previously identified by linkage analysis [7] followed by
deep sequencing to identify the underlying mutations. In
the remaining eight cases, Sanger sequencing of the
exons (including splice sites) of candidate genes in the
linked intervals was carried out. Details on identification
of the mutations are provided in Materials and methods.
In all cases, putative mutations were verified by PCR
and Sanger sequencing in larger cohorts (at least 100
mice per mutant line).
In the two cases in which a custom capture array was
used, we had an opportunity to obtain an estimate of the
ENU mutation rate. In one case four mutations werefound in the 4.2 Mbp captured interval and in the other
case six mutations were found. Based on these results
we estimated the ENU mutation rate at approximately 1
per Mbp. This is consistent with reports by others [31].
The heritability of the mutations was tested over at
least six generations. Flow cytometric expression profiles
and the percentage of erythrocytes expressing the trans-
gene for each MommeD (presented here for the first
time) are shown in Additional file 2.MommeD30 mice are haploinsufficient for Widely
interspaced zinc finger (Wiz)
MommeD30 was classified as an enhancer of variegation.
We mapped the MommeD30 mutation to a 1.9 Mbp
interval on chromosome 17 encompassing 48 genes
(Additional file 3). Exome deep sequencing identified a
single base deletion in exon 5 of the Wiz gene, causing a
frame shift mutation that is predicted to introduce a pre-
mature stop codon (Figure 2a and Table 1). No other pu-
tative ENU variants were identified in the linked region.
Wiz contains six Kruppel-type zinc finger motifs in a
widely interspaced manner and has been reported to associ-
ate with the histone H3 lysine 9 (H3K9) methyltransferases
G9a and GLP in cell lines [32,33]. No mouse mutants for
Wiz have so far been described. Western blot analysis using
an anti-Wiz antibody detected two bands (about 120 and
130 kDa), as expected, in wild-type embryos (Figure 2a).
Embryos heterozygous for the MommeD30 mutation
showed approximately half the amount of Wiz protein and
no Wiz protein was detected in homozygotes (Figure 2a).
We conclude that MommeD30 mice are haploinsufficient
for Wiz. We refer to this allele asWizMommeD30.MommeD18 carries a mutation in Rap interacting factor 1
(Rif1)
MommeD18 was classified as a suppressor of variegation
and candidate gene sequencing revealed that MommeD18
mice carry a nonsense mutation in exon 29 of the Rif1
gene (Figure 2b and Table 1). Two other candidate genes
(Epc2 and Mbd5) were sequenced and no mutations were
identified in these genes. Western blot analysis showed
approximately half the amount of full-length Rif1 protein
in MommeD18 heterozygotes and no full-length Rif1
protein in a homozygote (Figure 2b). Furthermore, a Rif1
gene trap allele (Materials and methods) had a similar ef-
fect on transgene expression as that observed with the
MommeD18 mutation, increasing the percentage of ex-
pressing cells in mice heterozygous for the gene-trap allele
(Additional file 4).
We conclude that the MommeD18 allele is the result
of a mutation in Rif1 that we refer to as Rif1MommeD18.
Rif1 has recently been shown to be involved in DNA
double strand break repair [34-37] and replication
Table 1 MommeD mutants, causative mutations and disease association
Name Effect on variegation Gene Nature of mutation Homozygous phenotype References Human homolog Disease association
MommeD1 Suppressor Smchd1 C->T exon 23; introduces Stop Null [5,11] SMCHD1 FSHD2 [14]
MommeD2 Suppressor Dnmt1 C->A exon 25; T812K Null [6] DNMT1 Schizophrenia, breast and prostate
cancer [15-19]
MommeD4 Enhancer Smarca5 T->A exon 12; W520R Hypomorphic? [5,6] SMARCA5 Acute myeloid leukemia [20]
MommeD5 Enhancer Hdac1 7 bp deletion in exon 13; Frameshift Null [5,7] HDAC1 Schizophrenia, neural development [2]
MommeD8 Enhancer Rlf G->T exon 8; C1558F Hypomorphic This study RLF
MommeD9 Enhancer Trim28 T->C splice donor site of intron 13 Null [8] TRIM28
MommeD10 Enhancer Baz1b T->G exon 7; L733R Hypomorphic [7] BAZ1B Williams-Beuren syndrome [21]
MommeD12 Enhancer eIF3h T->A - 10 bp before splice acceptor
site of intron 4
Null [9] eIF3H
MommeD13 Suppressor Setdb1 A->G exon 20; results in splicing defect Null This study SETDB1 Melanoma [22]
MommeD14 Suppressor Dnmt3b T->C splice acceptor site of intron 12 Hypomorphic [10] DNMT3B ICF syndrome [23]
MommeD16 Enhancer Baz1b T->C exon 2; L75P Hypomorphic? This study BAZ1B Williams-Beuren syndrome [21]
MommeD17 Suppressor Setdb1 T->C exon 21; V1248A Hypomorphic This study SETDB1 Melanoma [22]
MommeD18 Suppressor Rif1 C->T exon 29; Q1669 Stop Null This study RIF1 Breast cancer [24]
MommeD19 Suppressor Smarcc1 T->G splice acceptor site of intron 10 Null This study SMARCC1 Colorectal cancer [25,26]
MommeD23 Suppressor Smchd1 A->T exon 12; R498 Stop Null? This study SMCHD1 FSHD2 [14]
MommeD27 Suppressor Pbrm1 A->G exon 17; Y733C Hypomorphic? This study PBRM1 Renal cancer [27]
MommeD28 Enhancer Rlf A->G splice acceptor site of intron 4 Null This study RLF
MommeD30 Enhancer Wiz 1 bp deletion in exon 5; Frameshift at
amino acid 553
Null This study WIZ
MommeD31 Enhancer Trim 28 T->A exon 3; C178S Null? This study TRIM28
MommeD32 Suppressor Dnmt1 T->C exon 29; L1045P Null? This study DNMT1 Schizophrenia, breast and prostate
cancer [15-19]
MommeD33 Suppressor Suv39h1 A->G splice donor site of intron 1 Null This study SUV39H1 Lupus, retinoblastoma [2]
MommeD34 Enhancer Rlf C->A exon 7; C355 Stop Null This study RLF
MommeD35 Enhancer Smarca5 A-> G exon 9; N341S Hypomorphic? This study SMARCA5 Acute myeloid leukemia [20]
MommeD36 Suppressor Smchd1 C->T exon 42; Q1732 Stop Null? This study SMCHD1 FSHD2 [14]
MommeD37 Enhancer Smarca5 T->C exon 13; L565P Null? This study SMARCA5 Acute myeloid leukemia [20]
MommeD38 Enhancer eIF3h G->A exon 7; R291 Stop Null [9] eIF3H
MommeD39 Suppressor Smarca4 G->A splice donor site of intron 20 Null This study SMARCA4 Coffin-Siris syndrome [28]
MommeD40 Suppressor Uhrf1 T->A exon17; Y778 Stop Null This study UHRF1
MommeD42 Enhancer Brd1 T->A exon 11; C411 Stop Null This study BRD1 Schizophrenia, bipolar affective
disorder [29]
















Figure 1 An ENU mutagenesis/whole exome deep sequencing pipeline enables rapid identification of causative mutations in mice with
defects in epigenetic gene silencing. A schematic overview of the ENU mutagenesis gene discovery pipeline is presented. The major
components of the screen are described in the figure. Briefly, male FVB/NJ mice carrying an epigenetically sensitive GFP transgene (Line3) were
treated with ENU and mated with female Line3 mice. Offspring were screened for a shift in the percentage of GFP expressing erythrocytes using
flow cytometry. Putative mutants were mated with Line3 mice for four generations to test for heritability and reproducibility of the GFP
expression, and to reduce the number of non-causative ENU mutations within the genomes. Linkage analysis was carried out on the offspring
from two generations of backcrosses between putative mutants and C57BL/6J mice, which also carry the GFP transgene (Line3C). Causative
mutations were identified by whole exome deep sequencing, or gene candidate sequencing on individuals that had been maintained on the
Line3 background for at least seven generations. FACS, fluorescence-activated cell sorting.
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nificant chromatin reorganization. Our findings suggest
a role for Rif1 in transcription.
MommeD8, MommeD28 and MommeD34 carry mutations
in Rearranged L-myc fusion (Rlf), a gene about which little
is known
Three enhancers of variegation, MommeD8, MommeD28
and MommeD34, were found to carry mutations in Rlf.
Whole interval capture revealed that MommeD8 and
MommeD34 mice have mutations in exon 8 and exon 7,
respectively. MommeD8 is a missense mutation and
MommeD34 is a nonsense mutation (Figure 2c and
Table 1). TheMommeD28 mutation was identified by can-
didate sequencing and affects the splice acceptor site of in-
tron 4 (Figure 2c and Table 1). Western blot analysis using
two independent anti-Rlf antibodies (one polyclonal and
one monoclonal) detected an approximately 280 kDaband in protein lysates made from wild-type embryos
(Figure 2d). Although the band detected on the western
blots is substantially higher than the predicted molecular
weight of 218 kDa (NCBI Mouse Build 37), this could be
due to post-translational modifications to the Rlf protein.
We concluded that it is likely that this band is Rlf.
Reduced amounts (MommeD8) or no (MommeD28 and
MommeD34) Rlf protein was detected in homozygous em-
bryos (Figure 2d). Together, these results suggest that
MommeD8 is a hypomorphic allele and that MommeD28
and MommeD34 are null alleles.
Rlf encodes a protein predicted to contain 16 widely
spaced zinc finger domains, which has led to the sugges-
tion that it has a role in transcriptional regulation [40].
Rlf is conserved across vertebrates. To determine the
localization of Rlf in the cell, we carried out cell frac-
tionation experiments. Rlf protein was specifically
detected in the nuclear fraction of HeLa cells (Figure 2e).
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Figure 2 (See legend on next page.)
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Figure 2 Causative mutations in MommeD30, MommeD18, MommeD8, MommeD28 and MommeD34. (a) MommeD30 carries a 1 bp
deletion in Wiz that leads to a frame-shift at amino acid 553. Western blot analysis of embryo heads at 12.5 days post-coitum (dpc) shows
reduced levels of Wiz protein in WizMommeD30 heterozygotes and no Wiz protein in homozygotes. Wiz protein was detected at approximately 120
and approximately 130 kDa. Each track represents a different animal. Tubulin was used as a loading control. (b) MommeD18 harbors a point
mutation in Rif1 that introduces a premature stop codon at amino acid 1,669. Western analysis of testes tissue shows that RifMommeD18
heterozygotes have a reduced dosage of Rif1. No Rif1 protein was detected in a homozygote. Each track represents a different animal. Rif1
protein was detected at approximately 260 kDa and Tubulin was used as a loading control. (c) ENU point mutations in MommeD8, MommeD28
and MommeD34 occur in conserved regions of the Rlf protein. Asterisks indicate mutation. (d) Western blotting of Rlf in embryo head lysates
from 14.5 dpc Rlf+/+, RlfMommeD8/D8, RlfD28/D28 and RlfD34/D34 revealed greatly reduced amounts of Rlf protein. Each track represents a different
animal. Rlf protein was detected at approximately 280 kDa. Tubulin was used as a loading control. (e) Total, cytoplasmic and nuclear fractions of
HeLa cells were isolated and protein concentration quantified. Equal amounts of each fraction were immunoblotted with anti-Rlf, GAPDH
(cytoplasmic marker) and SMARCA5 (nuclear marker) antibodies, revealing nuclear localization of RLF. Rlf protein was detected at approximately
280 kDa, GAPDH protein at 37 kDa and SMARCA5 at approximately 120 kDa. (f) Coat color of offspring carrying the Avy allele produced from a
RlfMommeD8 heterozygous female crossed to a pseudoagouti Avy male. RlfMommeD8 heterozygous offspring showed a shift in coat color towards
pseudoagouti compared to wild-type littermates.
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mutants for Rlf and hereafter refer to these alleles as
RlfMommeD8, RlfMommeD28 and RlfMommeD34.
We have identified Rlf from a screen that is based on
the expression of a multi-copy variegating transgene. To
test if Rlf is required for the establishment of epigenetic
state at an endogenous locus, we studied the effect of
RlfMommeD8 on expression of agouti viable yellow (Avy).
Avy is a single copy gene that, like the transgene, is
known to be sensitive to epigenetic state [41]. The Avy
allele is the result of an intracisternal-A-particle (IAP)
retrotransposon insertion upstream of the agouti gene
and isogenic mice carrying the Avy allele can be yellow,
mottled or pseudoagouti (dark brown). Coat color has
been shown to correlate with the level of DNA methyla-
tion at the long-terminal repeat (LTR) promoter [42]. It
has been shown that haploinsufficiency for modifiers of
epigenetic reprogramming can alter the ratio of the dif-
ferent coat colors [5,6,43,44]. We crossed females het-
erozygous for RlfMommeD8 with pseudoagouti Avy/a mice
and scored the offspring for coat color. Offspring that
inherited the RlfMommeD8 allele were more likely to be
pseudoagouti than their wild-type littermates, that is,
haploinsufficiency for Rlf increased the probability of si-
lencing at the Avy locus (Figure 2f ). This is consistent
with Rlf being an enhancer of variegation and suggests
that Rlf has a general role in epigenetic regulation.
Novel alleles of known epigenetic regulators
In addition to the genes described above, we have pro-
duced 15 MommeD lines that carry mutations in genes
already known to be involved in epigenetic regulation in
the mouse. Exome deep sequencing of three suppressors of
variegation, MommeD19, MommeD27 and MommeD39,
identified mutations in the chromatin remodelers SWI/
SNF related, matrix associated, actin dependent regulator
of chromatin, subfamily c, member 1 (Smarcc1), Polybromo
1 (Pbrm1) and SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily a, member 4(Smarca4), respectively (Table 1). Smarcc1MommeD19 carries
a mutation in the splice acceptor site of intron 10 predicted
to lead to an in-frame premature stop codon and likely
nonsense-mediated mRNA decay. Quantitative real-time
RT-PCR and western blot analysis showed that Smarcc1
mRNA and Smarcc1 protein levels were reduced in hetero-
zygous animals (Figure 3a). The Pbrm1MommeD27 mutation
is a missense mutation in exon 17. Western blot analysis
revealed reduced levels of Pbrm1 protein in homozygotes
(Figure 3b). Smarca4MommeD39 has a mutation in the splice
donor site of intron 20. cDNA sequencing revealed an ex-
tended exonic sequence (data not shown) that is predicted
to lead to an in-frame premature stop codon and
nonsense-mediated mRNA decay. Quantitative real-time
RT-PCR analysis showed reduced Smarca4 mRNA in het-
erozygotes (Figure 3c).
MommeD42 was identified as an enhancer of variega-
tion and carries a nonsense mutation in exon 11 of
Bromodomain containing 1 (Brd1; Figure 3d and Table 1).
Brd1 has recently been reported to form a complex with
the histone acetyltransferase HBO1 and is required for
the transcriptional activation of the erythroid-specific
regulator genes in fetal liver [45].
Three suppressors of variegation were found to carry
mutations in H3K9 methyltransferases. MommeD13 and
MommeD17 carry mutations in Setdb1 and MommeD33
has a mutation in Suv39h1 (Table 1). The Setdb1MommeD13
mutation introduces a novel splice donor site leading to
an in-frame premature stop codon in exon 20 (Figure 3e).
cDNA analysis confirmed the presence of the predicted
transcript (data not shown). Setdb1MommeD17 is a missense
mutation in exon 21 of Setdb1 (Figure 3e). RNA analysis
indicates reduced levels of Setdb1 mRNA in the
MommeD13 mutants whereas Setdb1 mRNA levels were
not significantly different in the MommeD17 mutants
(Figure 3e). The Suv39h1MommeD33 mutation is at the
splice donor side of intron 20. This mutation is predicted
to lead to a premature stop codon. Consistent with this,
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Figure 3 (See legend on next page.)
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Figure 3 Causative mutations in MommeD19, MommeD27, MommeD39, MommeD42, MommeD13, MommeD33 and MommeD40.
(a) MommeD19 carries a mutation at a splice site of Smarcc1. Real-time RT-PCR and immunoblotting of embryos at 12.5 days post-coitum (dpc)
showed reduced levels of Smarcc1 mRNA and Smarcc1 protein in heterozygotes (n ≥ 5 mice). Each track represents a different animal. Smarcc1
protein was detected at approximately 160 kDa. (b) MommeD27 harbors a mutation in a bromodomain of Pbrm1. Western blot analysis of 14.5
dpc embryo heads showed reduced levels of Pbrm1 in homozygotes. Each track represents a different animal. Pbrm1 was detected at
approximately 190 kDa. (c) MommeD39 carries a mutation at a splice site of Smarca4. Real-time RT-PCR showed reduced Smarca4 mRNA in testes
of heterozygotes (n ≥ 4 mice). cDNA sequencing revealed that the mutation in Smarca4MommeD39 results in use of an alternative splice donor site.
(d) The mutation in MommeD42 introduces a premature stop codon at amino acid 411 of the Brd1 protein. (e) Mutations in MommeD13 and
MommeD17 occur in the conserved SET domain of Setdb1. Real-time RT-PCR of Setdb1 mRNA from testes of heterozygotes and age-matched
wild types (n = 4 mice). cDNA analysis revealed that the Setdb1MommeD13 allele is associated with the use of an alternative splice donor site in
exon 20, leading to a 62 bp truncation. (f) MommeD33 carries a mutation at a splice site in Suv39h1. Western blot analysis of Suv39h1 in adult
thymus showed reduced Suv39h1 in hemizygous mutant males. Each track represents a different animal. Suv39h1 protein was detected at 48
kDa. (g) The mutation in MommeD40 introduces a premature stop codon at amino acid 778 of Uhrf1. Western blot analysis of Uhrf1 revealed
greatly reduced levels in 9.5 dpc embryos homozygous for the Uhrf1MommeD40 mutation. Each track represents a different animal. Uhrf1 protein
was detected at approximately 90 kDa. Error bars indicate ± standard error of the mean. N.s., not significant. Asterisks indicate mutation.
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(Suv39h1 is on the X chromosome; Figure 3f).
MommeD40, a suppressor of variegation, carries a non-
sense mutation in exon 17 of the Uhrf1 gene (Figure 3g
and Table 1). Western blot analysis revealed greatly re-
duced levels of Uhrf1 protein in homozygous embryos
(Figure 3g). Uhrf1 is known to associate with the mainten-
ance DNA methyltransferase Dnmt1 [46] and has recently
been shown to link DNA methylation and H3K9 methyla-
tion in human cells [47].
Seven MommeD lines are new mutant alleles of
genes already identified in the screen and we have des-
ignated these lines Baz1bMommeD16, Smchd1MommeD23,
Trim28MommeD31, Dnmt1MommeD32, Smarca5MommeD35,
Smchd1MommeD36 and Smarca5MommeD37 (Table 1;
Additional file 5).
Approximately 60 Suppressor of variegation (Su(var))
and 25 Enhancer of variegation (E(var)) genes were iden-
tified in the Drosophila screens [2]. We have now docu-
mented 12 Su(var) and 8 E(var) genes in the mouse and
these encode some of the key factors for DNA methyla-
tion and H3K9 methylation, as well as a large group of
chromatin remodelers (Figure 4). Some of these genes,
such as Dnmt1, Suv39h and Trim28, have been identi-
fied as core heterochromatin factors, whereas others,
such as Smarca5 and Hdac1, have been associated with
gene silencing at euchromatic positions [2]. This is con-
sistent with the variegating phenotype of the transgene.
Interestingly, we have not yet recovered any members of
the RNA interference/piwi-interacting RNA (piRNA)
pathway or Polycomb and trithorax groups of proteins
but the screen has not reached saturation.
Momme genes are required for normal embryonic
development
In most of the MommeD lines, heterozygous mice were
observed at expected ratios at weaning and did not show
any obvious phenotypes. To determine the viability of
homozygotes, we performed embryonic dissectionsfollowing intercrosses. We have focused on those lines
carrying mutations in genes about which there is no or
few data available in the literature.
Following WizMommeD30 intercrosses, no homozygous
animals were recovered at weaning out of 97 progeny
(Figure 5a). To determine when WizMommeD30 homozy-
gotes died, embryos from intercross matings were
obtained at different stages of development and geno-
typed. Viable homozygotes were recovered at the
expected ratios at 10.5 days post-coitum (dpc). However,
these embryos appeared smaller than their wild-type and
heterozygous littermates. At 12.5 dpc homozygotes were
present in numbers less than expected (15% as opposed
to 25%) and at 14.5 dpc no viable homozygous embryos
were obtained (Figure 5a). We conclude from these data
that embryonic death in mice homozygous for
WizMommeD30 occurs between 10.5 and 12.5 dpc.
Rif1MommeD18 intercrosses produced wild-type and het-
erozygous offspring at the expected ratios and occasional
homozygous individuals (3 out of 155 offspring) at
weaning (Figure 5b). All surviving homozygotes were
males and two, out of three tested, were infertile. Timed
matings revealed that the majority of the homozygotes
died during the second half of gestation (Figure 5b). This
is consistent with the literature [48].
Rlf intercrosses produced homozygous individuals that
survived to weaning in less than expected numbers for
RlfMommeD8, RlfMommeD28 and RlfMommeD34 (Figure 5c).
RlfMommeD34 homozygotes died in the first week after
birth, for unknown reasons (Figure 5c). A similar finding
was made for RlfMommeD28 homozygotes; most died in
the first week after birth (data not shown). However, in
both lines some homozygotes did survive to adulthood
and were fertile (data not shown). Embryonic dissections
indicated that, for the RlfMommeD28 and RlfMommeD34
lines, late gestation homozygous embryos weighed sig-
nificantly less than their heterozygous or wild-type litter-
mates (T-test, P < 0.05; Figure 5c). RlfMommeD8 behaves
like a hypomorphic allele, with approximately half the
Figure 4 MommeD genes involved in transgene silencing in the mouse. Using an ENU mutagenesis screen, 18 unique genes were identified
to be involved in transgene silencing in the mouse. Factors are grouped by their broad mechanistic role in epigenetic regulation. TF, transcription
factor; Me, methyl. Figure adapted from [2].
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(Figure 5c). Those surviving were smaller and were fer-
tile (data not shown).
One advantage of ENU mutagenesis is that it produces
point mutations, increasing the likelihood of hypomorphic
mutations. We have reported hypomorphic alleles for
Smarca5MommeD4 and Dnmt3bMommeD14 previously [6,10].
In addition to the RlfMommeD8 allele described above,
SetdbMommeD17 behaves like a hypomorphic allele for
the following reasons. Following intercrosses, some
Setdb1MommeD17 homozygotes were present at weaning
(Figure 5d) and some survived to adulthood but were
smaller than their wild-type and heterozygous littermates
and showed decreased fertility (data not shown). Mice
homozygous for a null allele of Setdb1 have been reported
to die at the early post-implantation stage [49]. Consistent
with this, timed matings with Setdb1MommeD13 heterozy-
gous mice produced no viable homozygous offspring at
9.5 dpc (Figure 5d). To our knowledge, Setdb1MommeD17 is
the first hypomorphic allele for Setdb1.
In two cases, Smarcc1MommeD19 and Smarca4MommeD39,
heterozygous mutants showed signs of stochastic death
prior to weaning. Following Smarcc1MommeD19 inter-
crosses, no viable homozygotes were obtained at
weaning and timed matings revealed that homozygous
lethality occurred prior to mid-gestation, as expected
based on the literature [50] (Figure 5e). At weaning the
percentage of heterozygotes to wild types (47% and 53%,
respectively) was less than that expected (66% and 33%,
respectively). Maintenance of the colony, which involved
heterozygous to wild type crosses, also produced fewer
mutants than expected at weaning (34% as opposed to
50%) (Figure 5e). Further investigation suggested that
this stochastic death of heterozygotes was occurring
after 17.5 dpc and before 1 week postnatal (Figure 5e).At 17.5 dpc, some heterozygotes had exencephaly,
although this could not account for all the perinatal le-
thality observed (Figure 5e). The average weight of het-
erozygous mice at E17.5 and at 1 week postnatal was
reduced (T-test, P < 0.0001) and greater variance (F-test,
P < 0.05) was observed among heterozygotes than
among wild-type littermates (Figure 5e).
Maintenance of the Smarca4MommeD39 colony (hetero-
zygote to wild type crosses) also revealed non-
Mendelian ratios; heterozygotes were present in less
than expected numbers at weaning (18% as opposed to
50%) and were smaller than their wild-type littermates
(Figure 5f ). Timed matings showed that the ratios were
close to Mendelian prior to birth (Figure 5f ). Body
weights of heterozygotes were lower than those of wild-
type littermates at weaning (T-test, P < 0.0001) and,
again, the variance was greater in the heterozygotes
(F-test, P < 0.0001) (Figure 5f ). Similar stochastic death
of heterozygotes has been described by others for mice
with knock-out alleles for Smarcc1 and Smarca4 [50,51].
In these cases, however, the genetic heterogeneity among
the mice could have been an underlying factor.
We have previously reported increased variance in
body weight and behavioral responses in adult mice het-
erozygous for Trim28 [8] and others have made similar
findings with respect to Trim28 during the oocyte to
embryo transition [52]. We have also reported that re-
duced levels of Dnmt3a are associated with an increase
in body weight variance in adults [8]. These observa-
tions, in the context of inbred strains reared in con-
trolled environments, are consistent with a role for the
genes identified in this screen in canalization, a term
coined by Waddington to describe phenotypic robust-
ness during development. Exactly how important prob-
abilistic developmental events are in determining
Age +/+ D30/+ D30/D30
10.5 dpc 4 (20) 11 (55) 5 (25)
12.5 dpc 19 (36) 26 (49) 8 (15)*
14.5 dpc 16 (40) 20 (50) 4 (10)#
3 weeks 32 (33) 65 (67) 0 (0)
Age +/+ D18/+ D18/D18 EmptyDecidua
10.5-12.5 dpc 18 (23) 40 (51) 19 (24) 1 (1)
14.5 dpc 22 (28) 38 (49) 8 (10) 10 (13)
3 weeks 61 (39) 91 (59) 3 (2) na




















-/+ 3 weeks 25 (35) 40 (56) 7 (10)




















+/+ 3 weeks 249 (66) 129 (34) na na
Cross Age +/+ D39/+
MD39-/+ x MD39+/+ 14-16.5 dpc 28 (51) 27 (49)
MD39-/+ x MD39+/+ 17-18.5 dpc 13 (54) 11 (46)
MD39-/+ x MD39+/+ 3 weeks 192 (82) 43 (18)
Line Age +/+ -/+ -/- Chi-Test
MD34
-/+ 17.5 dpc 34  (34) 46 (46) 21 (21) ns
MD34
-/+ 1 week 24 (27) 55 (61) 11 (12) 0.02
MD34
-/+ 3 weeks 46 (32) 86 (60) 12 (8) < 0.0001
MD8
-/+ 3 weeks 133 (29) 254  (55) 71 (16) < 0.0001
MD28
-/+ 3 weeks 47 (38) 76 (61) 1 (1) < 0.0001
a b
Wiz Intercross Rif1 Intercross
* 8/8 homozygous mutants were developmentally delayed
# 4/4 homozygous mutants were dead
10.5 dpc
12.5 dpc
+/+            D30/+        D30/D30
14.5 dpc































































































































Genotype                   Genotype
MommeD19 (17.5 dpc) MommeD19 (1 week)
MommeD34 (17.5 dpc) MommeD28 (16.5 dpc)
Genotype                          Genotype
*T-test <0.0005; F-test <0.05 *T-test <0.05; F-test <0.05
*T-test <0.0001; F-test <0.05 **T-test <0.0001; F-test <0.0005
*T-test <0.0001; F-test <0.0001
Figure 5 (See legend on next page.)
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Figure 5 MommeD mutants show abnormal embryonic development. Timed matings and intercrosses of MommeD mutants.
(a) WizMommeD30 mice; data show the number of mice observed (and in brackets the percentage) at 10.5 days post-coitum (dpc), 12.5 dpc, 14.5
dpc and at weaning. Representative embryos are shown. (b) Rif1MommeD18 mice; data show the number of mice observed (and in brackets the
percentage) at 10.5 to 12.5 dpc, 14.5 dpc and at weaning. na, not applicable. (c) Rlf mutants; data show the number of mice observed (and in
brackets the percentage). Embryonic weights were measured from intercrosses of RlfMommeD34 and RlfMommeD28 mice. Homozygous embryos from
both had a significant increase in weight variation at 17.5 dpc or 16.5 dpc, respectively. Weights for each litter were normalized to the average
weight of wild-type embryos in that litter. Each data point represents an individual. Homozygotes were smaller than wild-type littermates at one
week after birth. ns, not significant. (d) Setdb1MommeD13 and Setdb1MommeD17 mice; data show the number of mice observed (and in brackets the
percentage). (e) Smarcc1MommeD19 and Smarcc1MommeD19 mated to wild-type mice revealed incomplete penetrance of heterozygous lethality after
birth. Data show the number of mice (and in brackets the percentage). Weights of 17.5 dpc Smarcc1MommeD19 embryos and pups were, on
average, less than that of wild-type littermates (T-test, P < 0.0001) and showed greater variation (F-test, P < 0.05). Weights in each litter were
normalized to the average weight of wild-type embryos in that litter. Each data point represents an individual. (f) Smarca4MommeD39 heterozygotes
showed reduced viability. Data show the number of mice and in brackets the percentage. Heterozygotes were smaller than their wild-type
littermates. Smarc4MommeD39/+ weighed less (T-test, P < 0.0001) and weights were more variable (F-test, P<0.0001) than wild types. Weights in
each litter were normalized to the average weight of wild-type embryos in that litter. Each data point represents an individual.
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only three measures; the penetrance of homozygous or
heterozygous death in the colony, the body weight
of heterozygotes or homozygotes (at various ages) in
the colony and behavioral responses. More extensive
phenotyping of these inbred MommeD lines should
enable us to gain a better understanding of this
phenomenon.




Uhrf1MommeD40 and Brd1MommeD41, we observed homo-
zygous embryonic death that is similar to that reported
for knock-out alleles of these genes (Additional file 6).DNA methylation levels at the transgene are increased in
Rlf mutants
Changes in transcription can correlate with changes
in DNA methylation at transgenes and metastable
epialleles [42,54-56]. We have shown previously that
changes in the percentage of red blood cells expressing
GFP can be accompanied by changes in DNA methyla-
tion at the transgene [7,10]. Using bisulfite sequencing,
we investigated DNA methylation at the HS-40 enhan-
cer region of the transgene in MommeD lines. We used
adult spleens from wild-type mice and mice heterozy-
gous for a MommeD mutation. Consistent with our pre-
vious reports, in Line3 wild-type mice around 60%
of the CpGs in the HS-40 element were methylated
(Figure 6a). Mice heterozygous for Dnmt1MommeD32 sug-
gested a decrease in CpG methylation (around 50%;
Figure 6a). This is consistent with an increase in expres-
sion of the GFP transgene in these mutants and with its
role as the maintenance DNA methyltransferase. In
mice heterozygous for the Wiz and Rif1 mutations DNA
methylation patterns at the HS-40 region were un-
affected (Figure 6b).In the case of the Rlf alleles, we detected higher lev-
els of DNA methylation at the HS-40 element in
adult spleens in RlfMommeD8 (82%, T-test <0.05) and
RlfMommeD34 (81%, T-test <0.05) homozygotes compared
to wild types (67%) (Figure 6d). A similar trend (not sta-
tistically significant) was observed in the RlfMommeD8
and the RlfMommeD34 heterozygotes compared with that
seen in Line3 wild-type (Figure 6a,c). In the case of
RlfMommeD28, where adult homozygotes are extremely
rare, we analyzed DNA methylation patterns in 16.5 dpc
embryos and made a similar finding. The HS-40 elem-
ent was more methylated in RlfMommeD28 homozygotes
(79%, T-test <0.05) than it was in wild-type controls
(51%) (Figure 6d). This is the first time that we have ob-
served hypermethylation of the transgene in a MommeD
line. An increase in DNA methylation at the transgene
locus in the Rlf mutants is consistent with the decreased
expression of the transgene in these mice.Conclusions
Our results suggest that transgene silencing in the
mouse acts through a mechanism common to trans-
poson silencing, X-inactivation and imprinting. We pro-
vide evidence that a novel gene, Rlf, is involved in this
process. Depletion of Rlf leads to DNA hypermethylation
at the transgene. How this is achieved is currently un-
known and requires further investigation. We have iso-
lated the first mouse mutants for Rlf and Wiz and
shown that the genes are required for normal embryonic
development. Notably, the human homologs of many of
the genes recovered from our screen have been found to
be associated with human diseases, in some cases identi-
fied in family studies and in other cases suggested by
genome-wide association studies (Table 1).
Since the mouse is often used as a disease model, we
anticipate that our collection of Momme mutants
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Rlf D8/D8* Rlf D34/D34*Rlf +/+ Rlf +/+ Rlf D28/D28*







*T-test <0.05 *T-test <0.05 *T-test <0.05
Figure 6 (See legend on next page.)
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Figure 6 Bisulfite sequencing of the HS-40 enhancer region of the GFP transgene. (a) DNA methylation levels were reduced in
Dnmt1MommeD32 heterozygous mice compared to wild-type mice in adult spleens (n = 4 wild-type mice and n = 2 Dnmt1MommeD32 mutant mice).
Filled circles represent methylated CpG sites. (b) DNA methylation levels in adult spleens were unaffected in mice heterozygous for WizMommeD30
and RifMommeD18 (n = 4 for WizMommeD30 and n = 2 for Rif1MommeD18). (c) DNA methylation levels in adult spleens of RlfMommeD8, RlfMommeD28 and
RlfMommeD34 heterozygotes were increased compared to wild-type mice (n = 2 mice for all genotypes). (d) Rlf homozygotes showed significantly
increased DNA methylation (T-test, P < 0.05) in adult male spleen (RlfMommeD8 and RlfMommeD34) and 16.5 dpc embryo (RlfMommeD28) compared to
wild types (n = 3 for all genotypes).
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Generation and screening of mutant mice
Procedures were approved by the Animal Ethics Commit-
tee of the QIMR Berghofer Medical Research Institute.
The ENU screen was carried out in the FVB/NJ inbred
transgenic line, Line3, which is homozygous for a
multicopy GFP transgene, as described previously [5]. All
MommeD lines were maintained in this background and
are homozygous for the GFP transgene. All experimental
data: crosses to other lines, intercrosses, and so on, were
carried out using heterozygous MommeD mice five gener-
ations or more removed from the MommeD founder.
Other mouse strains
The congenic strain, Line3C, used for linkage studies, was
produced by crossing Line3 to C57BL/6J for 10 genera-
tions, selecting for mice carrying the transgene by flow cy-
tometry. Inbred C57BL/6J mice were purchased from
ARC Perth (Perth, WA, Australia). Rif1GT mice were gen-
erated by the Australian Phenomics Network from an em-
bryonic stem cell clone carrying a trapped Rif1 allele
(A045A01; German Gene Trap Consortium), crossed to
Line3C (C57BL/6J) and maintained on this background.
Flow cytometry
Mice were analyzed by flow cytometry at 3 weeks of age.
A drop of blood was collected in Osmosol buffer and
analyzed on a Guava easyCyte HT (Merck/Millipore,
Darmstadt, Germany). The data were analyzed by using
Guava InCyte software with a GFP-positive gate set to
exclude 99.9% of wild-type erythrocytes. Histograms
shown depict only the GFP fluorescence channel.
Linkage analysis
Heterozygous mutant MommeD mice, at least four
generations down from the founder, were backcrossed
twice to Line3C (see above) and phenotyped for GFP
expression by flow cytometry. DNA from tail tips was
used to perform linkage analysis. The Illumina GoldenGate
genotyping assay (Mouse Medium Density Linkage Panel)
was used for MommeD13, MommeD16 to MommeD19,
MommeD27, MommeD30, MommeD32, MommeD34,
MommeD35, MommeD37, MommeD39, MommeD40 and
MommeD42 on at least 12 wild-type and 12 heterozygous
mice from each line. The Mouse Medium Density Linkagepanel contains 766 measurable SNPs between C57BL/6J
and FVB/NJ. Samples were genotyped following the
Illumina protocol and genotype calls were made using the
Genotyping module of the GenomeStudio v1.1 software.
Only samples with a call rate >95 were accepted. Linked in-
tervals were identified based on LOD scores of 3 or higher
(Additional file 7).
For MommeD8, MommeD23, MommeD28, MommeD32,
MommeD33 and MommeD36 the linked chromosomes
were identified using microsatellite or SNP markers. Add-
itional markers were used to reduce the linked intervals
using wild-type and heterozygous mice. Mice wild-type for
the mutation should only have C57BL/6J chromosomes in
the linked region, while mice heterozygous for the mutation
should carry both C57BL/6J and FVB/NJ chromosomes.
ForMommeD13,MommeD16,MommeD18,MommeD23,
MommeD28, MommeD32, MommeD33 and MommeD35,
mutations were found using Sanger sequencing. For the
remaining MommeD lines deep sequencing approaches
were used.
Whole exome deep sequencing and interval capture
Mouse exomes were captured and sequenced using exome
capture reagents from either Agilent (SureselectXT
Mouse All Exon v.1, Santa Clara, CA, USA) or Roche
NimbleGen (SeqCap EZ Mouse Exome, version Beta 2,
110603_MM9_exome_rebal_2EZ_HX1, Madison, WI,
USA). The Agilent captures were carried out as detailed
in the manufacturer’s protocol (version 1.1.1), with the
following exceptions: a Bioruptor (Diagenode, Liège,
Belgium) was used for DNA shearing, producing frag-
ment sizes of approximately 200 to 300 bp, and sample
pooling/multiplexing was omitted. The Bioruptor sonic-
ation settings were 3 × 10 minutes on the low setting
with cycles of 30 seconds on and 30 seconds off. The
Roche NimbleGen captures were carried out as outlined
in the Illumina optimized Roche NimbleGen SeqCap
User’s Guide (version 1.0), also using the Bioruptor for
DNA fragmentation.
For two mutant lines, MommeD8 and MommeD34, a
4.2 Mbp linked interval was sequenced in full using
a custom capture array designed and manufactured
by Roche NimbleGen. MommeD8 was captured and
sequenced by Roche NimbleGen using Roche 454 se-
quencing (110317_MM9_mommeD8_Rocky_cap_HX3).
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and a homozygote. For MommeD34, a heterozygous mu-
tant was captured and sequenced in-house using the
same array capture design on 2.1M arrays with HX3
mixers, according to the Roche NimbleGen Arrays
User’s Guide, Illumina Optimized protocol (version 1.0).
SNP calling
The sequencing reads from the targeted sequence cap-
ture experiments were aligned to the mouse genome
(build 37, mm9) using the program bwa version 0.6.1
[57]. Datasets generated by Roche on the 454 platform
were mapped using bwa bwasw [58] while the remaining
datasets, generated on the Illumina HiSeq or GAIIx plat-
forms, were mapped using bwa aln, with default settings,
followed by bwa sampe with the default settings. The
resulting sam files were converted to bam files and
coordinate-sorted using SAMtools version 0.1.17 [59]
and PCR duplicates were subsequently eliminated using
the program Picard MarkDuplicates, version 1.48 [60].
For each sample, nucleotide variants were identified
within the intervals for which linkage had previously been
determined. This was achieved by creating a pileup file of
the linked region using SAMtools mpileup, using the op-
tion -q 20, followed by variant calling using the program
Varscan version v2.2.8 [61] using the 'somatic' feature and
the settings -min-coverage 15 and -min-var-freq 0.3.
Varscan somatic calls sequence differences between a case
and a control sample; as control the sequenced exome
from a different ENU mutant was used. The case and con-
trol exomes were constructed using the same library prep-
aration methods and sequenced in the same deep
sequencing run, but had different linked intervals. All
exomes were mapped and processed in parallel, using
identical settings, to minimize post-sequencing artifacts.
The output from Varscan was manually screened for likely
ENU mutations, appearing as heterozygous SNPs in the
mutant and wild type in the control. These SNPs were in
turn validated using the Sanger method.
The custom capture and sequencing of the MommeD34
linked region was carried out in-house without a matched
wild-type control; instead, a merge of the threeMommeD8
deep sequencing samples previously sequenced by Roche
was used as control. A merge of these 454 datasets was
used in order to achieve greater read depth across the re-
gion. SNP calling was subsequently carried out as de-
scribed above. Exome sequencing datasets generated in
this study are accessible via European Nucleotide Archive
(ENA) under accession ERP003831.
Genotyping
Once the mutations had been identified, genotyping
was carried out by either sequencing (MommeD13,
MommeD16, MommeD17, MommeD18, MommeD23,MommeD27, MommeD28, MommeD30, MommeD32,
MommeD34, MommeD35, MommeD36, MommeD37,
MommeD39, MommeD40 and MommeD42) or, if the
mutation had changed a restriction enzyme recognition
site, by PCR and digestion and gel electrophoresis
(MommeD8 and MommeD19). Genotyping primers are
provided in Additional file 8 and Sanger sequencing
traces in Additional file 9.
Embryo dissections
All embryos were produced by natural matings and
detection of a vaginal plug was counted as 0.5 dpc.
Except where otherwise stated, embryos were produced
by intercrosses.
Introduction of the mutant lines into mice carrying the
Avy allele
FVB/NJ mice heterozygous for the MommeD8 mutation
and homozygous for the GFP transgene were mated with
C57BL/6J mice heterozygous for the Avy allele. The coat
color phenotype was classified at weaning by a trained
observer as either yellow, mottled, or agouti. GFP ex-
pression was determined by flow cytometry and used to
classify the mice into mutants or wild-type for the
MommeD8 mutation. FVB/NJ mice carry the A locus
and C57BL/6J mice carry the a locus. Yellow and mot-
tled offspring carry the Avy allele. All agouti-colored off-
spring were genotyped by PCR, to assess whether they
were Avy/A and pseudoagouti, or A/a, as reported [56].
Bisulfite sequencing of the transgene HS-40 enhancer
Bisulfite conversion of DNA was carried out using the
EpiTect Bisulfite Kit (Qiagen, Doncaster, VIC, Australia)
according to the manufacturer’s instructions. At least two
male adult spleens were used for each MommeD line. The
bisulfite conversion rate was at least 97% and sequences
were analyzed using the BiQ Analyser software [62]. Oli-
gonucleotides to the bisulfite converted HS-40 enhancer
region were as follows (5’-3’): GFPbisF1: AAAATAAAA
TTTTTGGATTGTTATTATTATAA; GFPbisF2: ATATT
TGTAATTTTAGTATTTTGGGAGGTT and GFPbisR: A
ATCTCTACTCACTACAAACTCCATCTC. Cycling con-
ditions were as follows: 94°C for 2 minutes for 1 cycle; 94°C
for 30 seconds, 60°C for 30 seconds, 72°C for 45 seconds
for 35 cycles and 72°C for 6 minutes for 1 cycle.
Protein analysis
Whole-cell extracts were prepared from various tissues of
adult mice. Protein concentration was measured by BCA
(Thermo Scientific, Waltham, MA, USA) and protein ly-
sates were separated using polyacrylamide gels (Invitrogen,
Carlsbad, CA, USA, BioRad, Hercules, CA, USA or ECL,
Rydalmere, NSW, Australia). Antibodies used were as fol-
lows: anti-γ-tubulin (T5192, Sigma-Aldrich, St. Louis, MO,
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anti-Wiz (gift from Yoichi Shinkai), anti-Smarcc1 (9053S,
Cell Signaling, Danvers, MA, USA), anti-Rlf (ab115011,
Abcam - rabbit polyclonal) and (M05, clone2G2, Abnova -
mouse monoclonal, Neihu District, Taipei City, Taiwan),
anti-Pbrm1 (Rabbit polyclonal ABE70, Millipore), anti-
Suv39h1 (clone D11B5, Cell Signaling), anti-Uhrf1
(ab151187 Abcam), anti-GAPDH (D16H11 XP, Cell Signal-
ing) and anti-Snf2H (ab3749, Abcam).
Cell fractionation
HeLa cells were trypsinized, pelleted and washed twice with
phosphate-buffered saline before re-suspending in ice-cold
cytoplasmic extraction buffer (10 mM Tris pH 7.4, 10 mM
NaCl, 3 mM MgCl2, 0.1% NP-40). A small aliquot of this
suspension, the total cell lysate, was transferred to a sepa-
rated tube. The remaining suspension was then centrifuged
(500 rpm, 10 minutes, 4°C) to pellet the nuclei. The super-
natant (cytoplasmic fraction) was aliquoted into a separate
tube. Nuclei were re-suspended in an 8 M urea lysis buffer
(8 M urea, 1/10 vol. glycerol, 1/20 vol. 20% SDS, 1/2,000
vol. 1 M dithiothreitol, 1/100 vol. 1 M Tris, pH 6.8).
RNA isolation, cDNA analysis and quantitative real-time
RT-PCR
Total RNA was extracted from various tissues using TRI re-
agent (Invitrogen). cDNA was synthesized from total RNA
using SuperScriptIII reverse transcriptase (Invitrogen) or
AMV reverse transcriptase (Roche) and random hexamer
primers. Quantitative real-time PCR was performed with
the Platinum SYBR Green qPCR Super Mix -UDG
(Invitrogen) with primers designed to span exon/intron
boundaries. All reactions were performed in triplicates and
normalized to Hprt or Gapdh. PCRs were run on a Viia7
(Applied Biosystems, Mulgrave, VIC, Australia) or on a
Corbett Research Rotor-Gene (Qiagen). Cryp-Skip [63] was
used for splice site prediction. cDNA from mutant alleles
was sequenced using Sanger sequencing. Primer sequences
are provided in Additional file 8.
Statistical analysis
Statistical significance of quantitative data was deter-
mined by two-tailed Student’s T-test. F-test was used to
test whether variance was significantly different between
wild-type and mutant groups. The proportions of geno-
types were compared to expected Mendelian ratios using
a χ2 test. For all datasets a minimum of three biological
replicates were analyzed.
Additional files
Additional file 1: Linked intervals. Manhattan plots showing linked
intervals identified by Illumina GoldenGate SNP genotyping analysis. Thex-axis represents the chromosomes and the y-axis is the LOD score. Peaks
with a LOD score of 3 or higher are considered significant.
Additional file 2: Flow cytometric profiles of the MommeDs.
(a) Representative flow cytometry profiles show the percentage of GFP-
expressing erythrocytes from wild-type and heterozygous mutant
littermates (n = 3). The x-axis represents the erythrocyte fluorescence on
a logarithmic scale and the y-axis is the number of cells detected at each
fluorescence level. (b) Percentage of GFP-expressing cells in wild-type,
heterozygous mutant and homozygous mutant (where viable) mice at
three weeks of age (mean ± standard error of the mean).
Additional file 3: Mapping interval for MommeD30. (a) MommeD30
was produced in the FVB/NJ strain of mice and mapped by crossing
twice onto Line3C in a C57BL/6J background. The results of the
genotype for seven SNP markers and one microsatellite marker
surrounding the linked interval are shown. The number of mice classified
into each haplotype is shown on top. Our estimate of the linked interval
is between rs29539305 and rs33446195 on chromosome 17 (highlighted).
(b) List of genes in the MommeD30 linked interval on chromosome 17.
The Mus musculus Ensembl database (release 37) was used to export a
list of transcripts (protein coding and non-coding RNAs) within the 1.9
Mbp MommeD30 interval.
Additional file 4: GFP expression in offspring of a Rif1GT
heterozygote crossed to Line3C. A Rif1 gene trap allele (Rif1GT) had a
similar effect on transgene expression as that observed with the
MommeD18 mutation, increasing the percentage of expressing cells in
mice heterozygous for the gene-trap allele.
Additional file 5: Novel mutant alleles of Baz1b, Smchd1, Trim28,
Dnmt1 and Smarca5. (a) MommeD16 carries a point mutation resulting
in a non-conservative amino acid change in the Wstf domain of Baz1b.
(b) MommeD23 and MommeD36 carry point mutations in Smchd1. Both
mutations introduce premature stop codons in the Smchd1 protein. (c)
MommeD31 carries a point mutation in Trim28 that results in an amino
acid change in a highly conserved zinc finger domain. (d) MommeD32
carries a point mutation that results in an amino acid change in the BAH
domain of Dnmt1. (e) MommeD35 and MommeD37 carry mutations that
result in amino acid changes in highly conserved domains of the
Smarca5 protein.
Additional file 6: Embryonic development in MommeD mutants.
Tabulated data shows the number of observed mice and in brackets the
percentage of total. (a) Intercrosses of Pbrm1MommeD27 mice produce no
homozygous offspring at three weeks. (b) Brd1MommeD42 homozygous
mice are embryonic lethal around 10.5 dpc. (c) Mice carrying mutations
in Suv39h1MommeD33 are viable at three weeks. (d) Uhrf1MommeD40
homozygotes are embryonic lethal around 10.5 dpc. (e) Some
homozygous Baz1bMommeD16 mice were obtained at three weeks but less
than expected. (f) No (Smchd1MommeD36) or few (Smchd1MommeD23)
homozygous individuals were recovered from intercrosses. The
Smchd1MommeD23 homozygotes that survived were males. (g)
Trim28MommeD31 homozygous mice are embryonic lethal prior to 10.5 dpc.
(h) Mice homozygous for the Dnmt1MommeD32 mutation die around 10.5
dpc. (i) Intercrosses of Smarca5MommeD35 and Smarca5MommeD37 produced
no homozygous offspring at three weeks. Timed matings show that
survival of homozygous mutants at 12.5 to 14.5 dpc was rare in
Smarca5MommeD35 mutants. In Smarca5MommeD37 mutants homozygous
embryonic death occurred prior to 14.5 dpc.
Additional file 7: Linkage analysis using Illumina GoldenGate
genotyping assay.
Additional file 8: List of primer sequences.
Additional file 9: Sanger traces.Abbreviations
bp: base pair; dpc: days post-coitum; ENU: N-ethyl-N-nitrosourea;
FSHD2: facioscapulohumeral dystrophy type 2; GFP: green fluorescent
protein; H3K9: histone H3 lysine 9; Momme: Modifier of murine metastable
epiallele; PCR: polymerase chain reaction; SNP: single-nucleotide
polymorphism.
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